Media Contact:

    Pam Lord
    Canale Communications
    619-849-6003
    plord@canalecomm.com

NPI-0052 Published Manuscripts

1) Caspase-8 dependent Histone Acetylation by a Novel Proteasome Inhibitor, NPI-0052: a Mechanism for Synergy in Leukemia cells; C Miller, S Rudra, M Keating, W Wierda, M Palladino, J Chandra. BLOOD (113, 4289-4299, 2009).

2) Discovery and Development of the Anticancer Agent Salinosporamide A (NPI-0052), W. Fenical, P.R. Jensen, M.A. Palladino, K.S. Lam, G.K. Lloyd, and B.C. Potts: Bioorg. Med. Chem. 2009, 17, 2175-80.

3) Leaving Groups Prolong the Duration of 20S Proteasome Inhibition and Enhance the Potency of Salinosporamides, R.R. Manam, K.A. McArthur, T-H. Chao, J. Weiss, J.A. Ali, V.J. Palombella, M. Groll, G.K. Lloyd, M.A. Palladino, S.T.C. Neuteboom, V.R. Macherla, and B.C.M. Potts, Journal of Medicinal Chemistry 52, 6711-6724, 2008.

4) Growth of Salinispora tropica Strains CNB440, CNB476, and NPS21184 in Nonsaline, Low-sodium Media; G. Tsueng and K.S. Lam: Appl. Microbiol. Biotechnol. 80, 873-880, 2008.

5) Proteasome Inhibition Activates EGFR and EGFR-independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells: Implications for Combination Therapy; C.M. Sloss, F. Wang, R. Liu, L. Xia, M. Houston, D. Ljungman, M. Palladino, J. Cusack, Jr. Clinical Cancer Research, 14, 5116-5123, 2008.

6) Inhibition of YY1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor, NPI-0052, Contributes to its TRAIL-enhanced Apoptosis in Cancer Cells; S. Baritaki, E. Suzuki, K. Umezawa, D. Spandidos, J. Berenson, T.R. Daniels, M.L. Penichet, M. Palladino, B. Bonavida; J. Immunology, 180; 6199-6210, 2008.

7) Dual Targeting of the Proteasome Regulates Survival and Homing in Waldenstrom Macroglobulinemia; A. Roccaro, X. Jia, A. Sacco, M. Melhem, A. Moreau, X Leleu, H. Ngo, J. Runels, A. Azab, F. Azab, N. Burwick, M. Farag, S. Treon, M. Palladino, T. Hideshima, D. Chauhan, K. Anderson, I. Ghobrial. Blood, 111: 4752-4763, 2008.

8) Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma; A. Chauhan, A Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. Palladino and K. Anderson. Blood 111:1654-1664, 2008.

9) A Low-Sodium Salt Formulation for the Fermentation of Salinosporamides by Salinispora Tropica strain NPS21184. G. Tsueng and K.S. Lam. Appl Microbiol Biotechnol, 78:821-826, 2008.

10) Defined Salt Formulations for the Growth of Salinispora Tropica Strain NPS21184 and the Production of Salinosporamide A (NPI-0052) and Related Analogs; G. Tsueng, S. Teisan and K.S Lam. Appl Microbiol Biotechnol, 78:827-832, 2008.

11) Salinosporamide A (NPI-0052) Potentiates Apoptosis, Suppresses Osteoclastogenesis, and Inhibitis Invasion Through Downmodulation of NF kB Regulated Gene Products; K. S. Ahn, G. Sethi, T.H. Chao, S. Neuteboom, M. Chaturvedi, M. Palladino, A. Younes, and B. Aggarwal; Blood 110: 2286-2295, 2007.

12) NPI-0052, a Novel Proteasome Inhibitor, Induces Caspase-8 and ROS Dependent Apoptosis Alone and in Combination with HDAC Inhibitors in Leukemia Cells; C. Miller, K. Ban, M. Dujka, D. McConkey, M. Palladino, and J. Chandra: Blood 110: 267-277, 2007.

13) Enantioselective Total Synthesis of (-)-Salinosporamide A (NPI-0052); T. Ling, V. Macherla, R. Manam, K. McArthur, B. Potts. Organic Letters, 9:2289-2292, 2007.

14) A Mechanistic and Kinetic Study of the β-Lactone Hydrolysis of Salinosporamide A (NPI-0052), a Novel Proteasome Inhibitor; N. Denora, B. Potts and V. Stella. Journal of Pharmaceutical Sciences, 96: 2037-2047, 2007.

15) Stabilization Effect of Resin on the Production of Potent Proteasome Inhibitor NPI-0052 During Submerged Fermentation of Salinispora Tropica; G. Tsueng and K.S. Lam. J Antibiotics: 60: 469-472, 2007.

16) Stereoselective Reduction of Keto-Salinosporamide to (-)-Salinosporamide A (NPI-0052); R. Manam, V. Macherla, and B. Potts. Tetrahedron Letters, 48: 2537-2540, 2007.

17) Unique Butyric Acid Incorporation Patterns for Salinosporamides A and B Reveal Distinct Biosynthetic Origins; G. Tsueng, K. Reed, B. Potts and K. Lam; Applied Microbiology and Biotechnology, 75: 999-1005, 2007.

18) Effect of Halogens on the Production of Salinosporamides by the Obligate Marine Actinomycete Salinispora tropica; K. Lam, G. Tsueng, K. Reed, S. Mitchell, B. Potts and J. Xu: J. Antibiotics: 60: 13-19, 2007.

19) Salinosporamides D-J from the Marine Actinomycete Salinispora Tropica, Bromosalinosporamide and Thioester Derivatives are Potent Inhibitors of the 20S Proteasome; K. Reed, R. Manam, S. Mitchell, J. Xu, S. Teisan, T. Chao, G. Yazdi, S. Neuteboom, K. Lam and B. Potts; J. Natural Products. 70: 269-276, 2007.

20) Crystal Structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in Complex with the 20S Proteasome Reveal Important Consequences of β-Lactone Ring Opening and a Mechanism for Irreversible Binding; M. Groll, R. Huber, and B. Potts: J. American Chemical Society: 128: 5136-5141, 2006.

21) The Proteasome Inhibitor NPI-0052 is a More Effective Inducer of Apoptosis than Bortezomib in Lymphocytes from Patients with Chronic Lymphocytic Leukemia (CLL); S. Ruiz, Y. Krupnik, M. Keating, J. Chandra, M. Palladino, and D. McConkey: Molecular Cancer Therapeutics 5(7), 1836-1843, 2006.

22) NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model; J. Cusack, R. Liu, L. Xia, C, Pien, W. Niu, V. Palombella, T. Chao, S. Neuteboom, and M. Palladino: Clinical Cancer Research 12(22), 6758-6764, 2006.

23) A Novel Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib; D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades, H. Yasui, A. Letai, H. Ovaa, C. Berkers, B. Nicholson, T. Chao, S. Neuteboom, P. Richardson, M. Palladino, and K Anderson: Cancer Cell: 8: 407-419, 2005.

24) Structure – Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor; V. Macherla, S. Mitchell, R. Manam, K. Reed, T. Chao, B. Nicholson, G. Deyanat-Yazdi, B. Mai, P. Jensen, W. Fenical, S. Neuteboom, K. Lam, M. Palladino, and B. Potts: J. Medicinal Chemistry: 48, 3684-3687, 2005.


NPI-0052 Published Abstracts and Posters

1) Clinical Trial of NPI-0052 in Advanced Malignancies Including Lymphoma and Leukemia (Advanced Malignancies Arm); A.R. Townsend, M. Millward, T. Price, P. Mainwaring, A. Spencer, A. Longenecker, M.A. Palladino, G.K. Lloyd, M.A. Spear, P. Padrik: J Clin Oncol 27:15s, 2009 (suppl; abstract #3582)

2) Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/refractory Multiple Myeloma (rr/MM); C. Hofmeister, P. Richardson, T. Zimmerman, M. A. Spear, M.A. Palladino, A.M. Longenecker, G. F. Cropp, G.K. Lloyd, A. L. Hannah, K. Anderson: J. Clin Oncol 27:15s, 2009 (suppl; abstract #8505)

3) First-in-Human Phase 1 Study of the Novel Structure Proteasome Inhibitor NPI-0052; P.A. Hamlin, C. Aghajanian, A. Younes, D.S. Hong, M.A. Palladino, A.M. Longenecker, G.K. Lloyd, A. L. Hannah, M.A. Spear, R. Kurzrock: J Clin Oncol 27:15s (suppl; abstract #3516)

4) Caspase-8 and Oxidant Dependenet Hyper-Scetylation of Histone-H3 by the Novel Proteasome Inhibitor NPI-0052; C. Miller, S. Rudra, M. Keating, W. Weirda, M. Palladino, and J. Chandra: AACR (abstract #5633), Denver, CO April 18-22, 2009

5) Analysis of Reactive Oxygen Species (ROS) Generation and Caspase-8 Activation by Analogs of Proteasome Inhibitor NPI-0052; R. Hale, C. Miller, R Manam, V. Macherla, M. Palladino, B. Potts and J. Chandra: AACR (abstract #5634), Denver, CO, April 18-22, 2009

6) The Proteasome Inhibitor NPI-0052 Inhibitis Metastasis via Inhibition of SNAIL-Induced EMT and Induction of the Tumor Metastasis Suppressor RKIP; S. Baritaki, A. Chapman, K. Young, M. Palladino, B. Bonavida: AACR (abstract #1194), Denver, CO, April 18-22, 2009

7) The Chlorine Leaving Group of the Proteasome Inhibitor NPI-0052 is Key to its Potency, Durability of Proteasome Inhibitiion and May Influence its Efflux Rate from Tumor Cells; T Chao, B. Wahlgren, A. Obaidat, J. Weiss, R. Manam, K. McArthur, V. Macherla, M. Palladino, B. Hagenbuch, B. Potts, S. Enna, G.K. Lloyd, S. Neuteboom: AACR (abstract #4539), Denver, CO, April 18 - 22, 2009

8) NPI-0052 (2nd Generation Proteasome Inhibitor) Phase 1 Trial in Patients with Solid Tumors and Lymphomas; R. Kurzrock, P. Hamlin, M. Gordon, D. Hong, S. Fu, A. Younes, A. Naing, A. Hannah, M. Palladino, M. Spear, A. Longenecker, S. Neuteboom, G. Cropp, G.K. Lloyd, C. Aghajanian, ENA-EORTC-AACR, Geneva, Sept 2008

9) Phase 1 Trial of the 2nd Generation Proteasome Inhibitor NPI-0052 in Patients with Advanced Malignancies with CLL and Lymphoma RP2D Cohorts; A. Townsend, P. Padrik, P. Mainwaring, T. Price, L. Catley, A. Longenecker, M. Palladino, G.K. Lloyd, G. Cropp, M. Spear, M. Millward, ENA-EORTC-AACR, Geneva, Sept 2008

10) Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL; T. Price, P. Padrik, A. Townsend, P. Mainwaring, L. Catley, A. Longenecker, G. Cropp, M. Palladino, G.K. Lloyd, M. Spear, M. Millward, ASH (abstract #7446), San Francisco, Dec, 2008

11) First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor; P. Hamlin, C. Aghajanian, D. Hong, A. Younes, M. Palladino, A. Longenecker, G. Cropp, G.K. Lloyd, A. Hannah, M. Spear, R. Kurzrock, ASH (abstract #3913), San Francisco Dec, 2008

12) Phase 1 Study of the Novel Proteasome Inhibitor NPI-0052 in Patients with Advanced Malignancies Including Leukemias; P. Padrik, T. Price, M. Spear, A. Townsend, A. Longenecker, M. Palladino, G.K. Lloyd, G. Cropp, M. Millward, European Society for Medical Oncology, Geneva, Sept, 2008

13) Leaving Groups Prolong the Duration of 20S Proteasome Inhibition and Enhance the Inhibition Profile of Salinosporamides. B. Potts, R. Manam, V. Macherla, T. Chao, J. Weiss, M. Groll, K. McArthur, S. Neuteboom, M. Palladino, G. K. Lloyd, European Journal of Cancer Supplements, 6(12), 74 (abstract #237) 2008.

14) Design and Synthesis of Highly Potent Non-Halogen Leaving Group Analogues of Salinosporamide A (NPI-0052); V. Macherla, R. Manam, K. McArthur, J. Weiss, Ta-H. Chao, S. Neuteboom and B. Potts. ISMC, Vienna, Austria, August 2008.

15) The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase Inhibitor Protein RKIP) in B-NHL via Inhibition of the Transcription Repressor Snail: Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis; S. Baritaki, A. Chapman, K. Wu, K. Yeung, D. Spandidos, J. Berenson, M. Palladino, B. Bonavida. ASH (abstract #2611) 2008.

16) Pharmocodynamic and Efficacy Studies of a Novel Proteasome Inhibitor NPI-0052 in Human Plasmacytoma Xenograft Mouse Model; A. Singh, G. K. Lloyd, M. Palladino, D. Chauhan and K. Anderson. ASH (abstract #3665) 2008.

17) Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in vivo Synergistic Cytotoxicity in Multiple Myeloma; D. Chauhan, A. V. Singh, G. Bianchi, M. Brahmandam, K. Podar, T. Hideshima, N. Munshi, P. Richardson, M. Palladino and K. Anderson. ASH (abstract #3662) 2008.

18) Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma; P. Richardson, C. Hofmeister, T. Zimmerman, A. Alban Chanankhan, M. Spear, M. Palladino, A. Longenecker, G.Cropp, G.K. Lloyd, S. Wear, A. Hannah, K. Anderson. ASH (abstract #277), 2008.

19) Halogen and non-halogen leaving groups enhance the potency of β-lactone proteasome inhibitors: Further investigation into the role of the halogen of NPI-0052 (salinosporamide A); T.H Chao, R. R. Manam, B. Hagenbuch, J. Weiss, K. McArthur, B. Wahlgren, V. Macherla, M. A. Palladino, S.T.C. Neuteboom, S. J. Enna, G. K. Lloyd, and B. C. Potts. Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic, an AACR Special Conference in Cancer Research, January 22-25, 2008, San Diego, California (Poster).

20) The Pharmacodynamic Profile of NPI-0052 is Cell-Type Specific; T. Chao, A. Barral, G. Lloyd, M. Spear, M. Palladino, S. Neuteboom. AACR (abstract #3257), 2008,

21) Inhibition of Snail-induced EMT and Induction of the Tumor Metastasis Suppressor/immune Cancer Gene RKIP by the Proteasome Inhibitor NPI-0052; Roles in Metastasis and Chemo/immunosensitization; S. Baritaki, K. Yeung, D. Chatterjee, B. Waterman, H. Chen, J. Berenson, M. Palladino, B. Bonavida. AACR (abstract #2572), 2008

22) Overlapping Functional Activities of Proteasome Inhibitor, NPI-0052, and HDAC Inhibitors Contribute to Synergistic Cytotoxicity in Leukemia Cells; C. P. Miller, M. Palladino, J. Chandra. AACR (abstract #3255), 2008

23) Dual Targeting of the Proteasome Regulates Survival and Homing in Waldenstrom Macroglobulinemia; A. Roccaro, X. Jia, A. Sacco, M. Melhem, A. Moreau, X Leleu, H. Ngo, J. Runels, A. Azab, F. Azab, N. Burwick, M. Farag, S. Treon, M. Palladino, T. Hideshima, D. Chauhan, K. Anderson, I. Ghobrial. AACR (abstract #3259), 2008

24) Phase 1 Clinical Trials of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors; R. Kurzrock, P. Hamlin, A. Younes, D. Hong, M. Gordon, M. Spear, M. Palladino, G. K. Lloyd, A. Longenecker, S. Neuteboom, G. Cropp, A. Hannah, C. Aghajanian. ASH 2007

25) Results from Phase 1 Dose Escalation Study of the Proteasome Inhibitor NPI 0052 in Patients with Solid Tumors and Lymphomas; R. Kurzrock, P. Hamlin, A. Younes, D. Hong, M. Gordon, A. Hannah, M.A. Palladino, G. K. Lloyd, A.M. Longenecker, S.T.C. Neuteboom, G.F. Cropp, M.A. Spear, C. Aghajanian. In: AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, 2007 Oct 22-26; San Francisco. CA, p 162. (abstract #B1), 2007.

26) From Sea Bed to Sick Bed: Discovery and Development of a Novel Proteasome Inhibitor, NPI-0052, from a Marine Actinomycete; K.S. Lam, Society for Industrial Microbiology, 2007

27) Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger in vivo Synergistic Cytotoxicity in Multiple Myeloma; D. Chauhan, A. Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. Palladino, K. Anderson ; ASH, Annual Meeting, Blood 110: 2524, 2007.

28) Induction of Raf-1 Kinase Inhibitory Protein (RKIP) by the Proteasome Inhibitor NPI-0052 and Reversal of B-NHL Resistance to Apoptosis; S. Baritaki, K. Yeung, D. Chatterjee, M. Palladino, B. Bonavida; ASH, Annual Meeting, Blood 110: 809, 2007.

29) Targeting Cdk4/6 in Combination Therapy Overcomes proteasome Inhibitor Resistance in Multiple Myeloma Through Synergistic Mitochondria Depolarization; X. Huang, T. Louie, M. Di Liberto, J. Rice, D. Jayabalan, K. Zhang, M. Palladino, I. Chen, P. Toogood, R. Niesvizky, M. A. S. Moore, S. Chen-Kiang; ASH, Annual Meeting, Blood 110: 667, 2007.

30) The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia; A. Roccaro, X. Leleu, A-S Moreau, X. Jia, A. Sacco, H. Ngo, A. Azab, F. Azab, E. Hatjiharissi, S. Treon, T. Hideshima, M. Palladino, K. Anderson, D. Chauhan, I. Ghobrial, ASH, Annual Meeting, Blood 110: 1516, 2007.

31) Lyophilization Development of NPI-0052 (Salinosporamide A) in Water/tert-Butyl Alcohol Co-solvent System; J.J. Chu, C. Billstrom, N. Reddinger, B. Mai, R. Singh and B.C.M. Potts. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, November 11 – 15, 2007.

32) A Novel Parenteral Formulation Design for NPI-0052 (Salinosporamide A), a β-Lactone Proteasome Inhibitor; J.J. Chu, C. Billstrom, N. Reddinger, B. Mai, R. Singh and B.C.M. Potts. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, November 11 – 15, 2007.

33) Stability Studies of Various Lyophilized Formulations and Dosing Solutions of NPI-0052, a Potent 20S Proteasome Inhibitor, to Support Parenteral Drug Product Development; N. Reddinger, B. Mai, C. Billstrom, J.J. Chu, R. Singh, and B.C.M. Potts. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, November 11 – 15, 2007.

34) A High Performance Liquid Chromatography (HPLC) Method for Quantitative Determination of NPI-0052 (Salinosporamide A) to Support Lyophilized Parenteral Drug Product Development; B. Mai, N. Reddinger, J.J. Chu, R. Singh, and B. Potts. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, November 11 – 15, 2007.

35) High Performance Liquid Chromatography Method Development for Quantitation of NPI-0052 in Formulated Drug Product with Polyvinylpyrrolidone as Excipient and Comparative Study of Evaporative Light Scattering vs. Ultra Violet Detection; R. Singh, N. Reddinger, B. Mai, J. Chu and B. Potts; 31st International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2007), June 17 – 21, Ghent, Belgium,

36) Pharmaceutical Development of a Parenteral Formulation of NPI-0052 (Salinosporamide A), a Novel Proteasome Inhibitor; R. Singh, B. Mai, C. Billstrom, M. Palladino, and B. Potts: American Pharmacists Association (APhA) Annual Meeting and Exposition March 16 – 19, Atlanta, GA, 2007.

37) Enantioselective Total Synthesis of (-)-Salinosporamide A (NPI-0052) and Analogues; T. Ling, V. Macherla, R. Manam, K. McArthur, and B. Potts. ASME, 2007.

38) Enantioselective Total Synthesis of (-)-Salinosporamide A (NPI-0052) and Analogues; T. Ling, V. Macherla, R. Manam, K. McArthur, and B. Potts. ACS, Boston, 2007.

39) Enantioselective Total Synthesis of (-)-Salinosporamide A (NPI-0052) and Analogues; T. Ling, V. Macherla, R. Manam, K. McArthur, and B. Potts. ASP, July, 2007.

40) Progress Towards an Enantioselective Total Synthesis of (-)-Salinosporamide A (NPI-0052); T. Ling, V. Macherla, R. Manam, K. McArthur, and B. Potts: AACR/ACS Meeting, San Diego, CA, February, 2007.

41) Stereoselective Enzymatic Conversion of Keto-Salinosporamide to Salinosporamide A (NPI-0052); R. Manam, V. Macherla, and B. Potts: AACR/ACS Meeting, San Diego, CA. February, 2007.

42) The Novel Proteasome Inhibitor, NPI-0052, Synergizes with HDAC Inhibitors to Trigger Apoptosis in Leukemia Cells; C. Miller and J. Chandra, AACR, Annual Meeting, Proceedings Abstract #2486, 2007.

43) Rituximab-Mediated Sensitization of Resistant B-NHL Cell Lines to the Proteasome Inhibitor NPI-0052 -Induced Apoptosis: Pivotal Role of PTEN Induction and Inhibition of Bcl-xL; E. Suzuk, M. Palladino, and B. Bonavida, AACR, Annual Meeting, Proceedings Abstract #1453, 2007.

44) Sensitization of B-NHL Resistant Tumor Cells Overexpressing Bcl-xL to TRAIL-Induced Apoptosis by the Novel Proteasome Inhibitor Salinosporamide A (NPI-0052); E. Suzuk, M. Palladino, G. Cheng and B. Bonavida. AACR, Annual Meeting, Proceedings Abstract 1445, 2007.

45) Proteasome Inhibitor NPI-0052 Exhibits a Distinct Biological Profile Compared to Non-leaving Group Analogs; B. Potts, T. Chao, J. Ali, A. Singh, R. Singh, S. Neuteboom, V. Palombella, D. Chauhan, K. Anderson and M. Palladino. AACR, Annual Meeting, Proceedings Abstract #4948, 2007.

46) A Novel Proteasome Inhibitor, NPI-0052 is Active in Hodgkin and Mantle Cell Lymphoma Cell Lines; D. Buglio, G. Georgakis, V. Yazbeck, T. Chao, S. Neuteboom, M. Palladino, and A. Younes. AACR, Annual Meeting, Proceedings Abstract #1454, 2007.

47) The Proteasome Inhibitor NPI-0052 Reduces Tumor Growth and Overcomes Resistance of Prostate Cancer to rhTRAIL via Inhibition of the NF-kB Pathway; A. Barral, T. Chao, S. Kanabolooki, G. Deyanat-Yazdi, B. Nicholson, D. McConkey, M. Palladino, and S. Neuteboom. AACR, Annual Meeting, Proceedings Abstract #1465, 2007.

48) Novel NF-B Inhibitors NPI-1342/NPI-1387 and Proteasome Inhibitor NPI-0052 Overcome Resistance of Pancreatic Carcinoma to rhTRAIL; S. Khanbolooki, S. Pino, R. Andtbacka, T. Chao, S. Neuteboom, M. Palladino, D. McConkey. AACR, 2006.

49) The Proteasome Inhibitor NPI-0052 Sensitizes Pancreatic Cancer Cells to TRAIL In Vitro and In Vivo; R. Andtbacka, S. Khanbolooki, M. Pino, K. Zhu, and D. McConkey: AACR, 2006.

50) Rituximab Sensitizes Resistant B-NHL Cell Lines to the Proteasome Inhibitor NPI-0052 – Induced Apoptosis; E. Suzuki, MB. Bonavida; AACR, 2006.

51) Salinosporamide A, a Novel Orally Active Proteasome Inhibitor NPI-0052 Enhances Tumoricidal Response to Multidrug Chemo-and Molecular Therapy Regimens in a Pancreatic Cancer Xenograft Model; J. Cusack, R. Liu, L. Xia, S. Neuteboom, and M. Palladino: ASCO, 2006.

52) Inhibition of the Pan-Bcl-2 Family by the Small Molecule GX15-070 Induces Apoptosis in Mantle Cell Lymphoma (MCL) Cells and Enhances the Activity of Two Proteasome Inhibitors (NPI-0052 and Bortezomib) and Doxorubicin Chemotherapy; V. Yazbeck, G. Georgakis, Y. Li., D. McConkey, M. Andreeff, and A. Younes: ASH, 2006.

53) Induction of RKIP and Inhibition of the Transcription Repressor YY1 in B-NHL by the Novel Proteasome Inhibitor NPI-0052 and Sensitization to TRAIL-Induced Apoptosis; E. Suzuki, S. Huerta-Yepez, S. Baritaki, M. Palladino, and B. Bonavida: ASH, 2006.

54) The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom’s Macroblobulinemia; X. Jia, XLeleu, A. Moreau, E. Hatjiharisi, H. Ngo, G. O’Sullivan, J. Runnels, D. McMillin, S. Treon, C. Mitsiades, T. Hideshima, M. Palladino, K. Anderson, D. Chauhan and I. Ghobrial ASH, 2006.

55) NPI-0052 (Salinosporamide A) is a Potent, Novel Proteasome Inhibitor that enhances the Tumoricidal Response to Conventional Multidrug Chemo – and Molecular Therapy in a Colon Cancer Xenograft Model; J. Cusack, R. Liu, L. Xia, S. Neuteboom, M. Palladino. AACR, 2005.

56) Reactive Oxygen Species Generation and Caspase 8 Activation are Required for Apoptosis Induction by a Novel Proteasome Inhibitor in Lymphoid Cells; C. Miller, S. Ruiz, S. Neuteboom, M. Palladino, D. McConkey, J. Chandra. AACR, 2005.

 

###

Nereus Pharmaceuticals is a registered trademark of Nereus Pharmaceuticals, Inc. All other product and company names may be registered trademark or trademarks of their respective owners.